GRDN

Company Overview — What Does Guardian Pharmacy Services, Inc. Do?

We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities (“LTCFs”) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We emphasize high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities (“ALFs”), and behavioral health facilities and group homes (collectively “BHFs”). More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs, which are our target markets, while the remainder has been generated primarily from residents of skilled nursing facilities (“SNFs”). Additionally, our robust capabilities enable us to serve residents in all types of LTCFs. We are a trusted partner to residents, LTCFs and health plan payors because we help reduce errors in drug administration, manage and ensure adherence to drug regimens, and lower overall healthcare costs. As of June 30, 2024, our 50 pharmacies served approximately 174,000 residents in approximately 6,700 LTCFs across 36 states. Within the U.S. LTCF market, we believe the ALF and BHF sectors present the most attractive opportunity and have the highest growth potential for our business. Certain characteristics of ALFs and BHFs, which are not typical of SNFs, create additional challenges and complexities for pharmacy service providers that Guardian is well suited to address. First, residents at ALFs are typically on a variety of different pharmacy benefit plans, each with a distinct formulary and reimbursement process, covering their complex drug regimens. Second, ALFs often lack staff with formal clinical training and usually do not have an on-site medical director or full-time nurse. Because residents of ALFs rely on off-site physicians to oversee and monitor their health conditions, there is an increased need for coordination among ALF operators, each resident’s physicians and pharmacy service providers. Third, residents in these facilities have the right to choose their own pharmacy, which often leads to multiple pharmacy service providers serving a single ALF. We believe that Guardian enjoys a strong competitive position as a large and purpose-built provider of pharmacy services to ALFs and BHFs. We offer a variety of services that we believe address the challenges that ALFs and BHFs face, and differentiate us from our competitors, providing residents, LTCFs and health plan payors with a compelling value proposition. Our centralized corporate support capabilities empower our local pharmacy operators to offer an extensive suite of high-touch, individualized, consultative pharmacy services, using a portfolio of proprietary data analytics systems and technology designed to help ensure that the right dose of the right medication is provided to the right resident at the right time. Examples of our specialized services include: • Assisting residents in optimizing pharmacy benefit plan coverage of their medication by coordinating formulary interchanges with residents’ physicians; • Proactively analyzing potential adverse drug interactions and managing potential risks in medication administration; • Providing robotic dispensing and customized compliance solutions, organized by resident and time of administration; • Integrating a resident’s drug regimen with the LTCF’s Electronic Medication Administration Records (“EMARs”) to help ensure adherence; • Providing training for LTCF caregivers to help them administer medications to residents more safely, efficiently and cost-effectively; • Partnering with LTCF operators to increase the number of residents using our services at each facility we serve, which we refer to as “resident adoption,” in order to streamline drug administration and minimize medication management risk; • Conducting mock audits of LTCFs to monitor compliance with drug administration and government regulation; and • Reviewing periodically the drug regimen for each resident by consulting pharmacists. --- We were originally formed as Guardian Pharmacy, LLC, an Indiana limited liability company, on July 21, 2003. On November 16, 2021, we formed Guardian Pharmacy Services, Inc., or Guardian Inc., as a direct, wholly owned subsidiary of Guardian Pharmacy, LLC. As a result of the Corporate Reorganization, Guardian Inc. will be a holding company and the sole manager of Guardian Pharmacy, LLC, with no material assets other than its 100% interest in Guardian Pharmacy, LLC; and Guardian Pharmacy, LLC will wholly own and be the sole member of each of the Converting Subsidiaries. In addition, Guardian Pharmacy, LLC will continue to be the majority owner of each of the Non-Converting Subsidiaries. Our principal executive offices are located at 300 Galleria Parkway SE, Suite 800, Atlanta, Georgia. Guardian Pharmacy Services, Inc. (GRDN) is classified as a mid-cap stock in the Consumer Discretionary sector, specifically within the Retail industry. The company is led by CEO Fred P. Burke, headquartered in ATLANTA, Georgia. With a market capitalization of $2.4B, GRDN is one of the notable companies in the Consumer Discretionary sector.

Guardian Pharmacy Services, Inc. (GRDN) Stock Rating — Hold (April 2026)

As of April 2026, Guardian Pharmacy Services, Inc. receives a Hold rating with a composite score of 47.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.GRDN ranks #518 out of 4,446 stocks in our coverage universe. Within the Consumer Discretionary sector, Guardian Pharmacy Services, Inc. ranks #32 of 442 stocks, placing it in the top 10% of its Consumer Discretionary peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GRDN Stock Price and 52-Week Range

Guardian Pharmacy Services, Inc. (GRDN) currently trades at $39.15. The stock lost $1.50 (3.7%) in the most recent trading session. The 52-week high for GRDN is $37.43, which means the stock is currently trading 4.6% from its annual peak. The 52-week low is $19.17, putting the stock 104.2% above its annual trough. Recent trading volume was 351K shares, suggesting relatively thin trading activity.

Is GRDN Overvalued or Undervalued? — Valuation Analysis

Guardian Pharmacy Services, Inc. (GRDN) carries a value factor score of 51/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 43.36x, compared to the Consumer Discretionary sector average of 24.47x — a premium of 77%. The price-to-book ratio stands at 11.59x, versus the sector average of 1.99x. The price-to-sales ratio is 1.85x, compared to 0.27x for the average Consumer Discretionary stock. On an enterprise value basis, GRDN trades at 8.69x EV/EBITDA, versus 4.91x for the sector.

Overall, GRDN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Guardian Pharmacy Services, Inc. Profitability — ROE, Margins, and Quality Score

Guardian Pharmacy Services, Inc. (GRDN) earns a quality factor score of 46/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -35.9%, compared to the Consumer Discretionary sector average of 6.2%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -18.9% versus the sector average of 2.5%.

On a margin basis, Guardian Pharmacy Services, Inc. reports gross margins of 19.6%, compared to 36.9% for the sector. The operating margin is -5.3% (sector: 3.8%). Net profit margin stands at -6.4%, versus 2.1% for the average Consumer Discretionary stock. Revenue growth is running at 20.1% on a trailing basis, compared to 3.3% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GRDN Debt, Balance Sheet, and Financial Health

Guardian Pharmacy Services, Inc. has a debt-to-equity ratio of 0.0%, compared to the Consumer Discretionary sector average of 89.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.38x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $36M.

GRDN has a beta of 0.69, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Guardian Pharmacy Services, Inc. is 59/100, reflecting average volatility within the normal range for its sector.

Guardian Pharmacy Services, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Guardian Pharmacy Services, Inc. reported revenue of $1.37B. Net income for the quarter was $-78M. Gross margin was 19.6%. Operating income came in at $-63M.

In FY 2025, Guardian Pharmacy Services, Inc. reported revenue of $1.45B. Net income for the quarter was $49M. Gross margin was 20.2%. Revenue grew 17.9% year-over-year compared to FY 2024. Operating income came in at $73M.

In Q3 2025, Guardian Pharmacy Services, Inc. reported revenue of $377M. Net income for the quarter was $10M. Gross margin was 19.8%. Revenue grew 20.0% year-over-year compared to Q3 2024. Operating income came in at $16M.

In Q2 2025, Guardian Pharmacy Services, Inc. reported revenue of $344M. Net income for the quarter was $9M. Gross margin was 19.8%. Operating income came in at $13M.

Over the past 8 quarters, Guardian Pharmacy Services, Inc. has demonstrated a growth trajectory, with revenue expanding from $1.05B to $1.37B. Investors analyzing GRDN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GRDN Dividend Yield and Income Analysis

Guardian Pharmacy Services, Inc. (GRDN) does not currently pay a dividend. This is common among smaller companies in the Retail industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Consumer Discretionary dividend stocks may want to explore other Consumer Discretionary stocks or use the stock screener to filter by dividend yield.

GRDN Momentum and Technical Analysis Profile

Guardian Pharmacy Services, Inc. (GRDN) has a momentum factor score of 68/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 10/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

GRDN vs Competitors — Consumer Discretionary Sector Ranking and Peer Comparison

Within the Consumer Discretionary sector, Guardian Pharmacy Services, Inc. (GRDN) ranks #32 out of 442 stocks based on the Blank Capital composite score. This places GRDN in the top decile of all Consumer Discretionary stocks in our coverage universe. Key competitors and sector peers include MONARCH CASINO & RESORT INC (MCRI) with a score of 50.5/100, CASEYS GENERAL STORES INC (CASY) with a score of 57.3/100, INGLES MARKETS INC (IMKTA) with a score of 51.0/100, FIVE BELOW, INC (FIVE) with a score of 51.6/100, and TARGET CORP (TGT) with a score of 52.6/100.

Comparing GRDN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GRDN vs S&P 500 (SPY) comparison to assess how Guardian Pharmacy Services, Inc. stacks up against the broader market across all factor dimensions.

GRDN Next Earnings Date

No upcoming earnings date has been announced for Guardian Pharmacy Services, Inc. (GRDN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GRDN? — Investment Thesis Summary

Guardian Pharmacy Services, Inc. presents a balanced picture with arguments on both sides. Price momentum is positive at 68/100, suggesting the trend favors buyers.

In summary, Guardian Pharmacy Services, Inc. (GRDN) earns a Hold rating with a composite score of 47.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GRDN stock.

Related Resources for GRDN Investors

Explore more research and tools: GRDN vs S&P 500 comparison, top Consumer Discretionary stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GRDN head-to-head with peers: GRDN vs MCRI, GRDN vs CASY, GRDN vs IMKTA.